



US GENERICS:

MONTHLY PRICE CHANGES – OCTOBER 2024



☎ +91 94997 68112

✉ nimish@researchdelta.com

30 Oct 2024


ABOUT THE REPORT

- The report highlights annual price changes in various dosage forms with monthly breaks – only for generic drugs
- The price reflects NADAC pricing as reported by Centers for Medicare / Medicaid Studies
- It covers ~60% of the ANDAs in the market


EXECUTIVE SUMMARY

- October 2024 witnessed modest change in price.
- NADAC values have fluctuated wildly between April – July 2024. This month on month volatility was ascribed to a large pharmacy's intermittent participation in the survey.
- Since last 3 months, the NADAC values have stabilised and have once again started reflecting the market reality.
- Except for dental products, all other dosage forms have witnessed a range bound pricing.
- Generic pricing had witnessed significant growth in the quarter of Oct-Dec 2023. This increase seems to have normalized now.

ORAL SOLIDS & LIQUIDS




INJECTABLES




INHALATION PRODUCTS




OPHTHALMIC / OTIC



TOPICALS



TRANSDERMAL




Premium Report


DENTAL PRODUCTS



OTHERS



OVERALL INDUSTRY



DOSAGE WISE UNIVERSE

Route Of Administration	No of ANDA
Injection	386
Topical	542
Oral	4784
Inhalation	122
Ophthalmic / Otic	199
Others	50
Transdermal	53
Dental	8
Total	6144

ANNEXURE 1: ROUT OF ADMINISTRATION CONSIDERED AS OTHERS

Route Of Administration

RECTAL

IRRIGATION

VAGINAL

PERFUSION,CARDIAC

IMPLANTATION

RECTAL,SUBLINGUAL

INJECTION,ORAL

INTRAVENOUS,ORAL

INJECTION,ORAL,RECTAL

INTRAPLEURAL

INTRACRANIAL

IONTOPHORESIS,TOPICAL

INHALATION,INTRAVENOUS

INTRADERMAL

INTRAMUSCULAR,ORAL

THANK
YOU